Evidence map›Paper›PMID 35187860›Full record

ArticleAnnals of clinical and translational neurology2022

Proteomic profiling of sporadic late-onset nemaline myopathy.

Elie Naddaf, Surendra Dasari, Duygu Selcen, M Cristine Charlesworth, Kenneth L Johnson, Michelle L Mauermann, Taxiarchis Kourelis

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Sporadic Late-Onset Nemaline Myopathy: Current Landscape.Current neurology and neuroscience reports · 2023
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Elie NaddafDivision of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6212-1236
Surendra DasariDepartment of Qualitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Duygu SelcenDivision of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
M Cristine CharlesworthMedical Genome Facility Proteomics Core, Mayo Clinic, Rochester, Minnesota, USA.
Kenneth L JohnsonMedical Genome Facility Proteomics Core, Mayo Clinic, Rochester, Minnesota, USA.
Michelle L MauermannDivision of Neuromuscular Medicine, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Taxiarchis KourelisDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo define the proteomic profile of sporadic late-onset nemaline myopathy (SLONM) and explore its pathogenesis.

methodsWe performed mass spectrometry on laser-dissected frozen muscle samples from five patients with SLONM, three of whom with an associated monoclonal protein (MP), and four controls, to determine the proteomic profile of SLONM. Furthermore, we assessed the role of the MP by evaluating the expression of the immunoglobulin light chain variable regions (IGVL).

resultsThere were 294 differentially expressed proteins: 272 upregulated and 22 downregulated. Among the top 100 upregulated proteins, the most common categories were: nuclear or nucleic acid metabolism (24%), extracellular matrix and basal lamina (17%), immune response (13%), and actin dynamics (8%). Downregulated proteins consisted mostly of contractile proteins. Among upregulated proteins, there were 65 with a role related to the immune system, including eight proteins involved in major histocompatibility complex 1 (MHC1) and antigen processing, 15 in MHCII complex and phagocytosis, and 23 in B and/or T-cell function. Among nine upregulated immunoglobulin proteins, there were two IGVL genes. However, these were also detected in SLONM cases without an MP, with no evidence of clonally dominant immunoglobulin deposition. In muscle sections from SLONM patients, nemaline rods tended to accumulate in atrophic fibers with marked rarefaction of the myofibrils. Increased MHC1 reactivity was present in fibers containing nemaline rods as well as adjacent nonatrophic fibers.

conclusionOur findings suggest that aberrant immune activation is present in SLONM, but do not support a direct causal relationship between the MP and SLONM.

Indexed as

Myopathies, NemalineHumansImmunoglobulinsMusclesProteomicsImmunoglobulins

Identifiers

PMID35187860
PMCPMC8935314
OpenAlexW4212774249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.